AstraZeneca’s experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
